HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yosuke Togashi Selected Research

Ligands

1/2022Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer.
11/2021TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment.
11/2020The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.
1/2019Clinical and immune profiling for cancer of unknown primary site.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yosuke Togashi Research Topics

Disease

54Neoplasms (Cancer)
10/2022 - 08/2008
41Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2021 - 01/2010
12Lung Neoplasms (Lung Cancer)
11/2021 - 03/2010
12Neoplasm Metastasis (Metastasis)
04/2020 - 03/2010
8Stomach Neoplasms (Stomach Cancer)
01/2020 - 12/2014
7Colorectal Neoplasms (Colorectal Cancer)
10/2021 - 05/2014
4Melanoma (Melanoma, Malignant)
11/2021 - 01/2014
4Adenocarcinoma of Lung
01/2020 - 02/2011
4Pancreatic Neoplasms (Pancreatic Cancer)
06/2017 - 05/2014
3Disease Progression
12/2020 - 05/2014
3Lymphoma (Lymphomas)
01/2020 - 10/2014
3Interstitial Lung Diseases (Interstitial Lung Disease)
01/2015 - 08/2012
2Microsatellite Instability
01/2022 - 10/2021
2Infections
09/2021 - 08/2011
2Exanthema (Rash)
01/2020 - 07/2013
2Squamous Cell Carcinoma (Epidermoid Carcinoma)
11/2016 - 08/2012
2Diarrhea
07/2013 - 10/2011
2Pneumonia (Pneumonitis)
07/2012 - 06/2010
2Small Cell Lung Carcinoma (Small Cell Lung Cancer)
07/2012 - 04/2011
2Pleural Effusion (Pleural Effusions)
09/2011 - 09/2010
2Chronic Kidney Failure (Chronic Renal Failure)
04/2011 - 05/2010
2Loeys-Dietz Syndrome
08/2008 - 01/2007
1Pathologic Complete Response
01/2022
1Rectal Neoplasms (Rectal Cancer)
01/2022
1Breast Neoplasms (Breast Cancer)
11/2021
1Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated)
09/2021
1Biliary Tract Neoplasms (Biliary Tract Cancer)
12/2020
1Esophageal Squamous Cell Carcinoma
04/2020
1Hodgkin Disease (Hodgkin's Disease)
01/2020
1Adenocarcinoma
01/2020
1Proteinuria
01/2020
1Squamous Cell Carcinoma of Head and Neck
01/2016

Drug/Important Bio-Agent (IBA)

21ErbB Receptors (EGF Receptor)IBA
01/2021 - 01/2010
15Erlotinib Hydrochloride (CP 358,774)FDA Link
06/2017 - 04/2010
12Tyrosine Kinase InhibitorsIBA
01/2021 - 05/2010
10Immune Checkpoint InhibitorsIBA
10/2022 - 01/2019
9Gefitinib (Iressa)FDA Link
01/2014 - 01/2010
6AfatinibIBA
12/2020 - 04/2015
5Phosphotransferases (Kinase)IBA
12/2016 - 04/2010
5Pharmaceutical PreparationsIBA
08/2015 - 09/2011
5Epidermal Growth Factor (EGF)IBA
01/2014 - 04/2010
4LigandsIBA
01/2022 - 01/2019
4Biomarkers (Surrogate Marker)IBA
11/2020 - 10/2011
4Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
01/2019 - 08/2015
4Formaldehyde (Formol)FDA Link
02/2015 - 02/2013
4ParaffinIBA
02/2015 - 02/2013
3NivolumabIBA
01/2022 - 01/2020
3Monoclonal AntibodiesIBA
01/2020 - 01/2019
3Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
12/2016 - 12/2014
3OSI-420IBA
09/2011 - 05/2010
2Programmed Cell Death 1 ReceptorIBA
10/2022 - 11/2020
2CateninsIBA
11/2021 - 01/2015
2Neoplasm Antigens (Tumor Antigens)IBA
11/2021 - 01/2019
2pembrolizumabIBA
11/2020 - 01/2019
2trametinibIBA
08/2015 - 12/2014
2GemcitabineFDA Link
07/2015 - 02/2011
2CrizotinibIBA
03/2015 - 10/2014
2Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA
03/2015 - 10/2014
2Activins (Activin)IBA
01/2015 - 05/2014
2Proteins (Proteins, Gene)FDA Link
08/2014 - 01/2014
2Transforming Growth Factor beta (TGF-beta)IBA
05/2014 - 08/2008
2Bevacizumab (Avastin)FDA Link
05/2014 - 08/2011
2Insulin-Like PeptidesIBA
09/2012 - 10/2011
2Insulin-Like Growth Factor Binding Protein 3IBA
09/2012 - 10/2011
2Pemetrexed (MTA)FDA Link
08/2012 - 03/2011
2Transforming Growth Factor beta Receptors (TGF beta Receptors)IBA
08/2008 - 01/2007
1Glucose (Dextrose)FDA LinkGeneric
01/2022
1Lactic Acid (Lactate)FDA LinkGeneric
01/2022
1RNA (Ribonucleic Acid)IBA
11/2021
1Protein Isoforms (Isoforms)IBA
11/2021
1Small Cytoplasmic RNAIBA
11/2021
1Calcibiotic Root Canal SealerIBA
10/2021
1T-Cell Antigen Receptors (T-Cell Receptor)IBA
10/2021
1Membrane Proteins (Integral Membrane Proteins)IBA
09/2021
1napabucasinIBA
11/2020
1atezolizumabIBA
04/2020
1Cisplatin (Platino)FDA LinkGeneric
04/2020
1Fluorouracil (Carac)FDA LinkGeneric
04/2020
1HLA Antigens (Human Leukocyte Antigens)IBA
04/2020
1regorafenibIBA
01/2020
1Nonesterified Fatty Acids (NEFA)IBA
01/2020
1Adrenal Cortex Hormones (Corticosteroids)IBA
12/2019
1Immune Checkpoint ProteinsIBA
01/2019
1Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
01/2019
1Fibroblast Growth Factors (Fibroblast Growth Factor)IBA
01/2017
1tyrosine receptor (receptor, tyrosine)IBA
12/2016
1Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA
11/2016
1nintedanibIBA
11/2016
1Carcinoembryonic AntigenIBA
11/2016
1Cetuximab (Erbitux)FDA Link
01/2016
1CollagenIBA
01/2016
1neratinibIBA
12/2015

Therapy/Procedure

26Therapeutics
01/2022 - 01/2010
12Drug Therapy (Chemotherapy)
04/2020 - 09/2010
11Immunotherapy
02/2022 - 01/2019
3Aftercare (After-Treatment)
12/2019 - 03/2015
2Chemoradiotherapy
01/2022 - 04/2020
2Radiotherapy
01/2020 - 01/2015
2Renal Dialysis (Hemodialysis)
04/2011 - 05/2010
1Precision Medicine
01/2019